Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

AstraZeneca pays up to $6.9 billion in Daiichi Sankyo cancer deal

AstraZeneca will pay up to $6.9 billion to work with Daiichi Sankyo on a hotly tipped experimental treatment for breast cancer, in a direct challenge to the world’s largest cancer drug maker Roche.

Read More »

Breast Ultrasound and Cancer Detection Rates Increased Under New Laws

  Participating in the Blue Cross Blue Shield Alliance for Health Research, the study comes from Yale’s School of Public Health and School of Medicine   NEW HAVEN, Conn., March 22, 2019 /PRNewswire/ –State breast density notification laws that mandate reporting of mammogram results can prompt further screening and modestly boost cancer detection rates, say […]

Read More »

FDA approves Roche’s small cell lung cancer treatment

Swiss drugmaker Roche Holding AG’s U.S. unit Genentech Inc. won approval for the immunotherapy Tecentriq for a tough-to-treat type of lung cancer.

Read More »

FDA approves Pfizer’s biosimilar to Roche’s Herceptin

The U.S. Food and Drug Administration approved Pfizer Inc.’s biosimilar to Roche AG’s blockbuster breast cancer treatment Herceptin.

Read More »

Roche’s Tecentriq and Companion Diagnostic Gets FDA Nod for Triple-Negative Breast Cancer

The U.S. Food and Drug Administration granted accelerated approval to Roche’s Genentech for Tecentriq (atezolizumab) plus chemotherapy (nab-paclitaxel) to treat unresectable locally advanced or metastatic triple-negative breast cancer in patients whose tumors expressed PD-L1.

Read More »

Roche adapts newer breast cancer drug in face of Herceptin imitations

Roche aims to broaden the use of the Swiss drugmaker’s Kadcyla breast cancer treatment as rivals crowd into the market with biosimilar copies of the company’s older mainstay product Herceptin.

Read More »

Samsung Bioepis biosimilar to Roche’s Herceptin wins FDA nod

The U.S. Food and Drug Administration approved a biosimilar to Roche Holding AG’s blockbuster breast cancer treatment Herceptin.

Read More »

Immunomedics’ cancer treatment fails to win accelerated approval from the FDA

The U.S. Food and Drug Administration declined to grant accelerated approval for Immunomedics Inc.’s breast cancer treatment sacituzumab.

Read More »

Investing Into R&D Pays off for Some of Biotech’s Biggest Companies

PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.

Read More »

FDA Approves Herceptin Biosimilar Herzuma

Celltrion Inc. and Teva Pharmaceutical Industries Ltd. announced that the U.S. Food and Drug Administration approved Herzuma (trastuzumab-pkrb), a HER2/neu receptor antagonist biosimilar to Herceptin (trastuzumab).

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

June 2019 Focus: Payer access, biotech/biopharma, DTC, rare diseases, and more!

Subscribe

Ad Right Bottom